What is the protocol for managing allergic anaphylactic shock, including post-shock treatment with steroids and fluids?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 7, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Anaphylactic Shock Protocol and Post-Shock Management

Immediate Treatment Protocol

Intramuscular epinephrine is the first and only first-line treatment for anaphylaxis and must be administered immediately—all other interventions are secondary and adjunctive. 1, 2

Primary Actions (Concurrent)

  • Administer epinephrine 0.01 mg/kg intramuscularly (1:1000 concentration) into the vastus lateralis (anterolateral thigh) 1, 3, 2

    • Maximum dose: 0.5 mg in adults, 0.3 mg in children/teenagers 1, 2
    • Repeat every 5-15 minutes if symptoms persist or progress 1, 3
    • There are no absolute contraindications to epinephrine in anaphylaxis 1, 3, 4
  • Remove/stop the allergen exposure immediately 1, 3

  • Call for help (911 or resuscitation team) but do not delay epinephrine administration 1, 3

Secondary Actions (Immediately Following Epinephrine)

  • Position the patient supine with lower extremities elevated if hypotension predominates 1, 5

    • If respiratory distress: sitting upright 1
    • If unconscious: recovery position 1
    • Never place in upright position during shock—this can be fatal 5
  • Establish IV access and administer rapid fluid bolus 1

    • Initial bolus: 500-1000 mL crystalloid (normal saline or balanced salt solution) in adults 1
    • Pediatric: 10-20 mL/kg bolus 1
    • Repeat boluses of 20 mL/kg as needed for persistent hypotension 1
    • May require up to 20-30 mL/kg total volume 1
  • Administer supplemental oxygen at 6-8 L/min 1, 3

  • Monitor vital signs continuously 1

Severity-Based Dosing Algorithm

Grade II (Moderate): Hypotension or bronchospasm requiring intervention

  • IV epinephrine 20 mcg (0.02 mg) if IV access present 1
  • If unresponsive at 2 minutes: 50 mcg (0.05 mg) IV 1
  • Crystalloid 500 mL rapid bolus, repeat as needed 1

Grade III (Severe): Life-threatening hypotension or bronchospasm

  • IV epinephrine 50-100 mcg (0.05-0.1 mg) 1
  • If unresponsive at 2 minutes: 200 mcg (0.2 mg) IV 1
  • Crystalloid 1 L rapid bolus, repeat as needed 1

Grade IV (Cardiac arrest)

  • Follow ACLS protocol with epinephrine 1 mg IV 1
  • Initiate CPR immediately 1
  • Rapid volume expansion 3

Refractory Anaphylaxis (>10 minutes without adequate response)

  • Escalate epinephrine dosing (double the bolus dose) 1

  • Start epinephrine infusion 0.05-0.1 mcg/kg/min peripherally 1, 3

    • Concentration: 4.0 mcg/mL 3
    • Titrate 1-4 mcg/min, maximum 10 mcg/min 3
  • Add second-line vasopressors for persistent hypotension: 1, 2

    • Norepinephrine 0.05-0.5 mcg/kg/min 1
    • Vasopressin 1-2 IU bolus, then 2 units/hour infusion 1
    • Dopamine 2-20 mcg/kg/min (400 mg in 500 mL D5W) 1, 2
  • For patients on beta-blockers unresponsive to epinephrine: 1, 3

    • Glucagon 1-5 mg IV over 5 minutes 1, 3
    • Follow with infusion 5-15 mcg/min titrated to response 1
    • Pediatric dose: 20-30 mcg/kg (maximum 1 mg) 1

Adjunctive Treatments (NEVER Before or Instead of Epinephrine)

For Bronchospasm

  • Inhaled beta-2 agonists (albuterol) after epinephrine for lower respiratory symptoms 1, 2
  • Consider IV bronchodilators (ketamine, salbutamol) if persistent after 10 minutes 1

Antihistamines (Second-Line Only)

  • H1 + H2 antagonist combination is superior to either alone 1, 2
  • Diphenhydramine 25-50 mg (1-2 mg/kg) IV slowly 1
  • Ranitidine 50 mg IV over 5 minutes (diluted in 20 mL) 1
  • Administer only after adequate epinephrine and fluid resuscitation 1
  • Never use promethazine—it is inappropriate for anaphylaxis 1

Post-Shock Management

Corticosteroids: Limited Role

Glucocorticoids have NO proven role in acute anaphylaxis treatment due to slow onset of action and should never delay or replace epinephrine. 1, 2

  • Not effective in preventing biphasic reactions 1
  • If given, use only for severe/prolonged reactions or patients with asthma 1, 2
  • Dosing: Methylprednisolone equivalent 1-2 mg/kg IV every 6 hours 1
  • The 2020 Anaphylaxis Practice Parameter recommends against routine use to prevent biphasic reactions 1

Observation Period

  • Minimum 6 hours observation in monitored setting after symptom resolution 1, 3
  • Extend to 24 hours for severe reactions or those requiring >1 dose of epinephrine 1, 3
  • Biphasic reactions occur in a minority of cases and are difficult to predict 6
  • Risk factors for biphasic reactions: 1
    • Severe initial presentation
    • Required >1 epinephrine dose
    • Wide pulse pressure
    • Unknown trigger
    • Drug trigger in children

Fluid Management Post-Shock

  • Continue IV crystalloid infusion as needed to maintain blood pressure 1
  • Monitor for fluid overload, especially after large volume resuscitation 1
  • Transition to maintenance fluids once hemodynamically stable 1

Critical Pitfalls to Avoid

  • Delaying epinephrine administration is associated with increased mortality and biphasic reactions 3, 2, 7
  • Using antihistamines alone or first is the most common error and significantly increases risk 1
  • Subcutaneous epinephrine delays absorption—always use intramuscular route 2
  • Placing patient upright during cardiovascular collapse can be fatal 5
  • IV epinephrine outside monitored settings or without proper dilution (use 1:10,000 for IV, not 1:1000) 1, 2
  • Assuming corticosteroids prevent biphasic reactions—they do not 1

Discharge Planning

  • Prescribe two epinephrine autoinjectors for all patients 2, 8
  • Provide written emergency action plan 1
  • Arrange allergist-immunologist follow-up for trigger identification 3
  • Document reaction severity, treatments given, and response 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Anaphylaxis Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Management of Anaphylaxis During Central Line Placement

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Diagnosis and management of anaphylaxis.

Journal of food allergy, 2020

Research

Anaphylaxis: Emergency Department Treatment.

Emergency medicine clinics of North America, 2022

Research

The role of epinephrine in the treatment of anaphylaxis.

Current allergy and asthma reports, 2003

Research

Epinephrine in the Management of Anaphylaxis.

The journal of allergy and clinical immunology. In practice, 2020

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.